- Home
- LH vs ROIV Comparison
LH vs ROIV Comparison
Compare LH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | ROIV |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United Kingdom |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 20.7B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LH | ROIV |
|---|---|---|
| Price | $267.76 | $29.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $311.33 | $28.94 |
| AVG Volume (30 Days) | 515.8K | ★ 4.3M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | ★ 18.33 | N/A |
| EPS | ★ 10.46 | N/A |
| Revenue | ★ $13,951,700,000.00 | $29,053,000.00 |
| Revenue This Year | $8.26 | N/A |
| Revenue Next Year | $4.81 | $744.61 |
| P/E Ratio | $25.86 | ★ N/A |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $214.02 | $10.18 |
| 52 Week High | $293.72 | $30.33 |
Technical Indicators
Market Signals| Indicator | LH | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 57.64 |
| Support Level | $259.07 | $20.46 |
| Resistance Level | $270.72 | $30.33 |
| Average True Range (ATR) | 6.72 | 0.90 |
| MACD | 0.18 | 0.13 |
| Stochastic Oscillator | 50.70 | 71.77 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.